Profile data is unavailable for this security.
About the company
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
- Revenue in USD (TTM)44.51bn
- Net income in USD7.73bn
- Incorporated1900
- Employees113.00k
- LocationAbbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
- Phone+1 (224) 667-6100
- Websitehttps://www.abbott.com/
Mergers & acquisitions
| Acquired company | ABT:NYQ since announced | Transaction value |
|---|---|---|
| Walk Vascular LLC | -11.11% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 12.16bn | 754.00m | 56.45bn | 41.00k | 75.17 | 3.37 | 30.47 | 4.64 | 0.5253 | 0.5253 | 8.47 | 11.71 | 0.3847 | 2.43 | 6.96 | 296,634.20 | 2.56 | 3.26 | 2.91 | 4.00 | 68.58 | 69.40 | 6.65 | 8.03 | 0.7787 | 5.91 | 0.3573 | 0.00 | 19.92 | 7.23 | 956.52 | 23.20 | 1.75 | -- |
| Edwards Lifesciences Corp | 5.36bn | 1.54bn | 58.67bn | 15.70k | 38.68 | 10.03 | 35.02 | 10.95 | 2.44 | 2.44 | 8.49 | 9.41 | 0.6853 | 1.67 | 8.76 | 341,216.60 | 19.68 | 15.99 | 22.16 | 18.95 | 76.58 | 75.11 | 28.72 | 23.63 | 2.64 | -- | 0.0925 | 0.00 | 19.29 | 12.04 | 82.55 | 21.42 | 8.69 | -- |
| Becton Dickinson and Co | 20.03bn | 1.83bn | 71.59bn | 75.00k | 39.60 | 2.92 | 17.44 | 3.57 | 6.34 | 6.34 | 69.37 | 86.03 | 0.3652 | 3.53 | 9.06 | 267,080.00 | 3.50 | 2.61 | 3.93 | 2.96 | 45.81 | 46.63 | 9.59 | 7.49 | 1.04 | 8.51 | 0.4318 | 72.79 | 18.29 | 10.16 | 161.02 | 15.45 | 11.39 | 4.69 |
| Intuitive Surgical, Inc. | 5.91bn | 1.64bn | 78.30bn | 9.79k | 48.62 | 6.47 | 38.99 | 13.26 | 4.49 | 4.49 | 16.11 | 33.72 | 0.4684 | 2.99 | 7.57 | 603,053.20 | 13.18 | 14.12 | 14.39 | 15.68 | 68.84 | 68.83 | 28.15 | 29.38 | 4.63 | -- | 0.00 | 0.00 | 31.01 | 16.10 | 60.72 | 18.22 | 45.67 | -- |
| Stryker Corporation | 17.43bn | 2.02bn | 87.16bn | 46.00k | 43.75 | 5.79 | 29.34 | 5.00 | 5.27 | 5.27 | 45.57 | 39.78 | 0.5009 | 1.85 | 6.22 | 378,913.00 | 5.79 | 6.73 | 6.58 | 7.95 | 62.91 | 64.75 | 11.56 | 13.16 | 1.18 | -- | 0.4838 | 42.39 | 19.21 | 8.60 | 24.70 | 3.90 | 1.39 | 11.20 |
| Medtronic PLC | 31.79bn | 4.91bn | 137.84bn | 90.00k | 28.29 | 2.63 | 18.05 | 4.34 | 3.63 | 3.63 | 23.51 | 39.14 | 0.3362 | 2.22 | 5.96 | 353,166.70 | 5.22 | 4.77 | 5.90 | 5.36 | 68.46 | 68.51 | 15.53 | 14.96 | 2.10 | 21.71 | 0.323 | 60.93 | 4.16 | 0.8752 | -25.94 | -0.2157 | 5.31 | 8.83 |
| Abbott Laboratories | 44.51bn | 7.73bn | 196.88bn | 113.00k | 25.96 | 5.56 | 17.65 | 4.42 | 4.33 | 4.33 | 24.94 | 20.22 | 0.6065 | 3.44 | 6.71 | 393,929.20 | 10.53 | 5.59 | 12.74 | 6.57 | 57.14 | 57.18 | 17.35 | 11.61 | 1.40 | 19.64 | 0.3242 | 63.22 | 24.47 | 15.61 | 57.24 | 46.08 | 10.95 | 11.60 |
| Thermo Fisher Scientific Inc. | 41.12bn | 7.60bn | 215.59bn | 130.00k | 28.68 | 5.26 | 20.60 | 5.24 | 19.20 | 19.20 | 103.78 | 104.63 | 0.5183 | 4.32 | 5.43 | 316,330.80 | 9.62 | 7.49 | 10.95 | 8.57 | 48.37 | 47.28 | 18.56 | 16.38 | 1.10 | 23.36 | 0.4471 | 6.77 | 21.71 | 16.50 | 21.18 | 30.70 | 41.55 | 10.76 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2022 | 144.27m | 8.18% |
| BlackRock Fund Advisorsas of 31 Mar 2022 | 86.38m | 4.90% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2021 | 84.13m | 4.77% |
| SSgA Funds Management, Inc.as of 31 Dec 2021 | 74.32m | 4.22% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2021 | 52.40m | 2.97% |
| Geode Capital Management LLCas of 31 Mar 2022 | 28.55m | 1.62% |
| Massachusetts Financial Services Co.as of 31 Mar 2022 | 25.88m | 1.47% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2022 | 25.37m | 1.44% |
| Polen Capital Management LLCas of 31 Mar 2022 | 22.42m | 1.27% |
| Morgan Stanley Investment Management Ltd.as of 31 Mar 2022 | 17.85m | 1.01% |
